JP2010535242A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535242A5
JP2010535242A5 JP2010520185A JP2010520185A JP2010535242A5 JP 2010535242 A5 JP2010535242 A5 JP 2010535242A5 JP 2010520185 A JP2010520185 A JP 2010520185A JP 2010520185 A JP2010520185 A JP 2010520185A JP 2010535242 A5 JP2010535242 A5 JP 2010535242A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disorder
tcg
disease
aacg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010520185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535242A (ja
JP5563455B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/071738 external-priority patent/WO2009018431A2/en
Publication of JP2010535242A publication Critical patent/JP2010535242A/ja
Publication of JP2010535242A5 publication Critical patent/JP2010535242A5/ja
Application granted granted Critical
Publication of JP5563455B2 publication Critical patent/JP5563455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010520185A 2007-08-01 2008-07-31 Ｔｌｒ９の新規な合成アゴニスト Active JP5563455B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US95325107P 2007-08-01 2007-08-01
US60/953,251 2007-08-01
US98360107P 2007-10-30 2007-10-30
US60/983,601 2007-10-30
US98715107P 2007-11-12 2007-11-12
US60/987,151 2007-11-12
US1529207P 2007-12-20 2007-12-20
US61/015,292 2007-12-20
PCT/US2008/071738 WO2009018431A2 (en) 2007-08-01 2008-07-31 Novel synthetic agonists of tlr9

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014120860A Division JP5816720B2 (ja) 2007-08-01 2014-06-11 Ｔｌｒ９の新規な合成アゴニスト

Publications (3)

Publication Number Publication Date
JP2010535242A JP2010535242A (ja) 2010-11-18
JP2010535242A5 true JP2010535242A5 (https=) 2013-05-02
JP5563455B2 JP5563455B2 (ja) 2014-07-30

Family

ID=40305273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010520185A Active JP5563455B2 (ja) 2007-08-01 2008-07-31 Ｔｌｒ９の新規な合成アゴニスト
JP2014120860A Active JP5816720B2 (ja) 2007-08-01 2014-06-11 Ｔｌｒ９の新規な合成アゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014120860A Active JP5816720B2 (ja) 2007-08-01 2014-06-11 Ｔｌｒ９の新規な合成アゴニスト

Country Status (12)

Country Link
US (2) US7960362B2 (https=)
EP (3) EP2821488B1 (https=)
JP (2) JP5563455B2 (https=)
KR (1) KR20100053598A (https=)
CN (3) CN105177014B (https=)
AU (1) AU2008282172B2 (https=)
BR (1) BRPI0813981A2 (https=)
CA (1) CA2693266C (https=)
ES (2) ES2539353T3 (https=)
IN (1) IN2010KN00195A (https=)
RU (1) RU2468819C2 (https=)
WO (1) WO2009018431A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
KR20100053598A (ko) * 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ９의 신규한 합성 효능제
US20110293565A1 (en) * 2009-01-30 2011-12-01 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
ES2534947T3 (es) 2009-03-25 2015-04-30 The Board Of Regents Of The University Of Texas System Composiciones para la estimulación de resistencia inmunitaria innata de mamíferos a patógenos
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
KR101898177B1 (ko) * 2013-01-08 2018-09-12 이데라 파마슈티칼즈, 인코포레이티드 톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CA2961019A1 (en) * 2014-09-12 2016-03-17 Vantage Specialty Chemicals, Inc. Derivatives of 1,3-propanediol
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP6991857B2 (ja) * 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
WO2017052403A1 (ru) * 2015-09-25 2017-03-30 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой микрорнк
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
TWI810193B (zh) 2017-07-05 2023-08-01 大陸商尚華醫藥科技（江西）有限公司 一種Kiss1肽類化合物、其應用及含其的組合物
WO2019066571A2 (ko) 2017-09-28 2019-04-04 연세대학교 산학협력단 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
AU2020310853A1 (en) 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
AU2021300632A1 (en) 2020-07-02 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of achieving HIV viral remission using long-acting antiretroviral agents
EP4295917A3 (en) 2020-08-07 2024-02-28 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6503734B1 (en) * 2000-07-26 2003-01-07 Cognis Corporation Cytochrome b5 gene and protein of Candida tropicalis and methods relating thereto
US6673613B2 (en) * 2000-07-26 2004-01-06 Cognis Corporation Use of CYP52A2A promoter to increase gene expression in yeast
RU2194502C2 (ru) * 2000-12-27 2002-12-20 Наровлянский Александр Наумович Иммуномодулятор - метаболик - детоксикант - адаптоген - радиопротектор
JP4188687B2 (ja) * 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション 免疫変調ポリヌクレオチド及びその使用法
CA2451974C (en) * 2001-06-21 2014-10-14 Karen L. Fearon Chimeric immunomodulatory compounds and methods of using the same
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
PT1992635E (pt) * 2002-12-23 2012-03-20 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
CA2524071A1 (en) * 2003-04-29 2004-11-11 Centocor, Inc. Toll-like receptor 9 effector agents and uses thereof
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
US20050244410A1 (en) * 2004-04-29 2005-11-03 Ashlyn Bassiri Toll-like receptor 9 effector agents and uses thereof
US20060014713A1 (en) * 2004-06-15 2006-01-19 Hybridon, Inc. Immunostimulatory oligonucleotide multimers
ES2544877T3 (es) * 2005-10-12 2015-09-04 Idera Pharmaceuticals Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
EP2371956A3 (en) * 2005-11-07 2012-01-04 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7786089B2 (en) * 2005-12-20 2010-08-31 Idera Pharmaceuticals, Inc. Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
MX2009006230A (es) * 2006-12-12 2009-06-22 Idera Pharmaceuticals Inc Agonistas sinteticos de receptores de tipo toll 9.
WO2008131074A1 (en) * 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
KR20100053598A (ko) * 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ９의 신규한 합성 효능제

Similar Documents

Publication Publication Date Title
JP2010535242A5 (https=)
JP7213566B2 (ja) 病原体ワクチンならびにその製造および使用方法
JP2013507905A5 (https=)
RU2010107207A (ru) Новые синтетические агонисты tlr9
CN1604795B (zh) 具有提高的活性的组合基序免疫刺激寡肽
JP4942646B2 (ja) 免疫賦活オリゴヌクレオチドマルチマー
ES2380796T3 (es) Oligonucleótidos inmunoestimuladores y sus usos.
JP2010532996A5 (https=)
JP2008501807A5 (https=)
JP2010512421A5 (https=)
CA2752694A1 (en) Synthetic rna-based agonists of tlr7
US20160194642A1 (en) Spherical nucleic acid-based constructs as immunoregulatory agents
US10378018B2 (en) RNA-based compositions and adjuvants for prophylactic and therapeutic treatment
ES2486298T3 (es) Análogos de oligonucleótidos inmunoestimuladores que contienen azúcares modificados
US12473553B2 (en) RNA nanostructures and methods of making and using RNA nanostructures
JP2009515823A5 (https=)
HRP20150566T1 (hr) Kompozicija za inhibiciju ekspresije gena i njegova upotreba
JP2010507386A (ja) オリゴリボヌクレオチドおよびその使用
JP2010504982A (ja) Ｔｌｒのリガンドと抗ウイルス剤との組成物
CN101160401A (zh) 免疫刺激寡核苷酸
WO2005083076A1 (ja) インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
CN103596594A (zh) 自身凝胶化核酸
WO2017007027A1 (ja) 免疫刺激オリゴヌクレオチド複合体
JP2013532976A5 (https=)
JP2023527525A (ja) インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法